A New Screening Strategy for 2019 Novel Coronavirus Infection
NCT ID: NCT04281693
Last Updated: 2020-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
230 participants
INTERVENTIONAL
2020-02-29
2020-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study for Novel Coronavirus Pneumonia (NCP)
NCT04283396
Pathogen Identification of Bacterial Pneumonia Via DNA Detection
NCT00567827
Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus
NCT04292327
Community-Acquired Pneumonia Diagnosis Through Integrating Novel Microbiological Techniques.
NCT06259110
Clinical Characteristics and Microbiology of Community-Acquired Pneumonia
NCT03098914
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Screening participants
Standard screening strategy
The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.
New screening strategy
The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard screening strategy
The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.
New screening strategy
The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing 302 Hospital
OTHER
Affiliated Hospital to Academy of Military Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan Liu
Role: PRINCIPAL_INVESTIGATOR
Beijing 302 Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the Fifth Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. Chinese.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
307-nCoV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.